The folate antimetabolite pemetrexed used in combination-treatment with cisplatin against pleural mesothelioma and non-small cell lung cancer was also a strong modulator of IRE1 RNase activity, with IC50 value of 0.26 ± 0.2. Here, ERN1 is linked to pleural mesothelioma.